Table 1 Study population, incidence rates and adjusted rate ratios of patients who developed HA-VTE and associated case fatality

 Medical

573,042

(17.20 %)

2,565

(6.72 %)

4.5

1.00

245

(6.59 %)

9.6 %

1.00

 Surgical

2,758,635

(82.80 %)

35,596

(93.28 %)

12.9

2.28

(2.19–2.38)

^d

3,471

(93.41 %)

9.8 %

1.05

(0.91–1.20)

 Female

1,693,109

(50.82 %)

19,805

(51.90 %)

11.7

1.00

1,730

(46.56 %)

8.7 %

1.00

 Male

1,638,568

(49.18 %)

18,356

(48.10 %)

11.2

0.93

(0.91–0.95)

^d

1,986

(53.44 %)

10.8 %

1.25

(1.17–1.33)

^d

  > =75 years & <90

1,074,206

(32.24 %)

15,350

(40.22 %)

14.3

1.00

1,832

(49.30 %)

11.9 %

1.00

  > =18 years & <35 years

396,444

(11.90 %)

1,742

(4.56 %)

4.4

0.53

(0.50–0.56)

^d

55

(1.48 %)

3.2 %

0.23

(0.17–0.30)

^d

  > =35 years & <55 years

707,274

(21.23 %)

5,612

(14.71 %)

7.9

0.83

(0.81–0.86)

^d

354

(9.53 %)

6.3 %

0.47

(0.41–0.52)

^d

  > =55 years & <75 years

1,153,753

(34.63 %)

15,457

(40.50 %)

13.4

1.13

(1.10–1.15)

^d

1,475

(39.69 %)

9.5 %

0.77

(0.72–0.83)

^d

 Married

1,803,208

(54.12 %)

20,814

(54.54 %)

11.5

1.00

2,089

(56.22 %)

10.0 %

1.00

 Single

1,372,496

(41.20 %)

15,730

(41.22 %)

11.5

0.90

(0.89–0.92)

^d

1,447

(38.94 %)

9.2 %

0.91

(0.85–0.98)

^c

 Unknown

155,973

(4.68 %)

1,617

(4.24 %)

10.4

0.83

(0.79–0.88)

^d

180

(4.84 %)

11.1 %

1.12

(0.96–1.31)

 Australia and New Zealand

2,411,315

(72.38 %)

26,794

(70.21 %)

11.1

1.00

2,575

(69.29 %)

9.6 %

1.00

 UK, US & Canada

223,710

(6.71 %)

2,873

(7.53 %)

12.8

1.01

(0.97–1.05)

271

(7.29 %)

9.4 %

0.90

(0.79–1.02)

 Non-English Europe

317,973

(9.54 %)

4,546

(11.91 %)

14.3

0.98

(0.95–1.02)

493

(13.27 %)

10.8 %

0.98

(0.88–1.08)

 North Africa

61,595

(1.85 %)

487

(1.28 %)

7.9

0.67

(0.61–0.73)

^d

47

(1.26 %)

9.7 %

1.09

(0.82–1.46)

 Asia

101,485

(3.05 %)

996

(2.61 %)

9.8

0.76

(0.71–0.81)

^d

98

(2.64 %)

9.8 %

1.11

(0.90–1.36)

 Others

215,599

(6.47 %)

2,465

(6.46 %)

11.4

0.94

(0.90–0.98)

^d

232

(6.24 %)

9.4 %

1.01

(0.88–1.16)

 1st quartile (most disadvantaged)

913,712

(27.42 %)

9,482

(24.85 %)

10.4

1.00

939

(25.27 %)

9.9 %

1.00

 2nd quartile (disadvantaged)

862,580

(25.89 %)

8,843

(23.17 %)

10.3

1.00

(0.97–1.03)

900

(24.22 %)

10.2 %

1.05

(0.95–1.16)

 3rd quartile (advantaged)

827,343

(24.83 %)

9,701

(25.42 %)

11.7

0.98

(0.95–1.01)

1,011

(27.21 %)

10.4 %

1.12

(1.01–1.23)

^c

 4th quartile (most advantaged)

728,042

(21.85 %)

10,135

(26.56 %)

13.9

0.99

(0.95–1.03)

866

(23.30 %)

8.5 %

1.13

(1–1.27)

^c

 2–4 days

1,495,477

(44.89 %)

4,803

(12.59 %)

3.2

1.00

567

(15.26 %)

11.8 %

1.00

 4–9 days

1,056,167

(31.70 %)

10,724

(28.10 %)

10.2

2.78

(2.69–2.88)

^d

816

(21.96 %)

7.6 %

0.69

(0.62–0.76)

^d

 Over 10 days

780,033

(23.41 %)

22,634

(59.31 %)

29.0

7.91

(7.65–8.17)

^d

2,333

(62.78 %)

10.3 %

0.82

(0.74–0.90)

^d

 Cardiac arrhythmias

74,686

(2.24 %)

657

(1.72 %)

8.8

-

22

(0.59 %)

3.3 %

-

 Chronic pulmonary disease

129,030

(3.87 %)

853

(2.24 %)

6.6

-

92

(2.48 %)

10.8 %

-

 Coagulopathy

5,455

(0.16 %)

211

(0.55 %)

38.7

-

15

(0.40 %)

7.1 %

-

 Congestive heart failure

71,705

(2.15 %)

971

(2.54 %)

13.5

-

130

(3.50 %)

13.4 %

-

 Diabetes with chronic complication

41,956

(1.26 %)

464

(1.22 %)

11.1

-

58

(1.56 %)

12.5 %

-

 Malignancies

206,407

(6.20 %)

3,796

(9.95 %)

18.4

-

860

(23.14 %)

22.7 %

-

 Metastatic solid tumour

49,332

(1.48 %)

1,427

(3.74 %)

28.9

-

368

(9.90 %)

25.8 %

-

 Peripheral vascular disease

26,225

(0.79 %)

425

(1.11 %)

16.2

-

61

(1.64 %)

14.4 %

-

 Pulmonary circulation disorders

1,520

(0.05 %)

73

(0.19 %)

48.0

-

10

(0.27 %)

13.7 %

-

 Renal disease

8,736

(0.26 %)

103

(0.27 %)

11.8

-

14

(0.38 %)

13.6 %

-

 Rheumatic disease

9,811

(0.29 %)

176

(0.46 %)

17.9

-

9

(0.24 %)

5.1 %

-

 Public

2,704,301

(81.17 %)

31,160

(81.65 %)

11.5

1.00

3,362

(90.47 %)

10.8 %

1.00

 Private

627,376

(18.83 %)

7,001

(18.35 %)

11.2

1.03

(0.85–1.25)

354

(9.53 %)

5.1 %

0.55

(0.43–0.71)

^d

 Principal referral (A1)

1,315,038

(48.63 %)

19,134

(61.41 %)

14.6

1.00

2,069

(61.54 %)

10.8 %

1.00

 Ungrouped acute (A3)

73,569

(2.72 %)

765

(2.46 %)

10.4

0.67

(0.46–0.95)

^c

132

(3.93 %)

17.3 %

2.71

(1.48–4.97)

^d

 Major metro- & non-metropolitan (B)

839,827

(31.06 %)

7,958

(25.54 %)

9.5

0.73

(0.60–0.89)

^d

817

(24.30 %)

10.3 %

1.22

(0.91–1.64)

 District group 1 (C1)

245,005

(9.06 %)

1,933

(6.20 %)

7.9

0.64

(0.51–0.81)

^d

198

(5.89 %)

10.2 %

1.75

(1.22–2.50)

^d

 District group 2 (C2)

230,862

(8.54 %)

1,370

(4.40 %)

5.9

0.48

(0.39–0.60)

^d

146

(4.34 %)

10.7 %

2.06

(1.44–2.95)

^d

 Major m

409,555

(65.28 %)

4,961

(70.86 %)

12.1

1.00

213

(60.17 %)

4.3 %

1.00

 District (22)

217,821

(34.72 %)

2,040

(29.14 %)

9.4

1.03

(0.64–1.64)

141

(39.83 %)

6.9 %

1.36

(0.79–2.34)

 Metropolitan

2,300,073

(69.04 %)

29,779

(78.04 %)

12.9

1.00

2,814

(75.73 %)

9.4 %

1.00

 Rural & Regional NSW

1,031,604

(30.96 %)

8,382

(21.96 %)

8.1

0.69

(0.59–0.81)

^d

902

(24.27 %)

10.8 %

1.18

(0.95–1.45)

Total

3,331,677

38,161

11.4

3,716

9.7 %